The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for autoimmune diseases, with chimeric antigen receptor (CAR)-T ther
The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
